治疗偏头痛的降钙素基因相关肽受体拮抗药:zavegepant

A new drug of calcitonin gene-related peptide receptor antagonists for the treatment of migraine:zavegepant

Zavegepant是2023年3月由美国食品药品监督管理局批准的首个降钙素基因相关肽(CGRP)受体拮抗药鼻腔喷雾剂,用于成人有先兆或无先兆偏头痛的急性治疗。Zavegepant是一种高选择性的CGRP受体拮抗药,最常见的药物不良反应主要为味觉障碍、恶心、鼻腔不适和呕吐。本文对zavegepant的作用机制、药代动力学、临床研究及安全性等方面进行介绍。

Objective Zavegepant was the first nasal spray of calcitonin gene-related peptide(CGRP)receptor antagonist approved by the US Food and Drug Administration(FDA)in March 2023 for the acute treatment of migraine with or without aura in adults.Zavegepant is a highly selective CGRP receptor antagonist.The most common adverse reactions were taste disorders,nausea,nasal discomfort and vomiting.This article introduced the mechanism of action,pharmacokinetics,clinical researches and safety of zavegepant.